Sanofi (ENXTPA:SAN) commences share repurchases on January 4, 2021, under the program mandated by the shareholders in the Annual General Meeting held on April 28, 2020. As per the mandate, the company is authorized to repurchase its own shares such that the company does not hold more than 10% shares in its treasury for a maximum amount of €18,807.69 million The shares will be repurchased at a maximum price of €150 per share. The purpose of the buyback is to implement share purchase option plans or similar plans and/or allotment or transfer of shares to salaried employees and/or to grant shares linked to stock option plans or other awards to salaried employees or corporate officers of the company or associated company and/or delivery of shares or the exercise of rights attached to securities giving access to the capital and/or cancellation of some or all of the repurchased shares, delivery of shares in connection with an acquisition, merger, demerger or asset-for-share exchange and/or liquidity to the shareholders. The authorization will be valid for a period of 18 months.